- Home
- CCAP vs CSTL Comparison
CCAP vs CSTL Comparison
Compare CCAP & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCAP
- CSTL
- Stock Information
- Founded
- CCAP 2015
- CSTL 2007
- Country
- CCAP United States
- CSTL United States
- Employees
- CCAP N/A
- CSTL N/A
- Industry
- CCAP Finance: Consumer Services
- CSTL Medical Specialities
- Sector
- CCAP Finance
- CSTL Health Care
- Exchange
- CCAP Nasdaq
- CSTL Nasdaq
- Market Cap
- CCAP 537.8M
- CSTL 558.7M
- IPO Year
- CCAP N/A
- CSTL 2019
- Fundamental
- Price
- CCAP $16.05
- CSTL $16.79
- Analyst Decision
- CCAP Strong Buy
- CSTL Strong Buy
- Analyst Count
- CCAP 5
- CSTL 6
- Target Price
- CCAP $18.50
- CSTL $38.33
- AVG Volume (30 Days)
- CCAP 109.0K
- CSTL 549.3K
- Earning Date
- CCAP 05-14-2025
- CSTL 05-05-2025
- Dividend Yield
- CCAP 11.84%
- CSTL N/A
- EPS Growth
- CCAP N/A
- CSTL N/A
- EPS
- CCAP 1.99
- CSTL N/A
- Revenue
- CCAP $197,363,000.00
- CSTL $347,083,000.00
- Revenue This Year
- CCAP N/A
- CSTL N/A
- Revenue Next Year
- CCAP N/A
- CSTL $3.14
- P/E Ratio
- CCAP $8.08
- CSTL N/A
- Revenue Growth
- CCAP 7.18
- CSTL 38.43
- 52 Week Low
- CCAP $13.54
- CSTL $15.70
- 52 Week High
- CCAP $20.19
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- CCAP 50.63
- CSTL 31.31
- Support Level
- CCAP $15.50
- CSTL $15.70
- Resistance Level
- CCAP $16.07
- CSTL $17.70
- Average True Range (ATR)
- CCAP 0.41
- CSTL 1.06
- MACD
- CCAP 0.11
- CSTL -0.36
- Stochastic Oscillator
- CCAP 63.71
- CSTL 15.25
About CCAP Crescent Capital BDC Inc. Common stock
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.